Dendritic cell vaccination for cancer therapy.
- Nestle FO Department of Dermatology, University of Zurich Medical School, Switzerland.
- 2001-06-28
Published in:
- Oncogene. - 2000
Antigens, Neoplasm
Clinical Trials as Topic
Dendritic Cells
Forecasting
Hematopoietic Stem Cells
Humans
Immunotherapy, Adoptive
Melanoma
Neoplasms
Vaccination
English
A growing list of defined tumor-antigens opens the way to antigen specific immunotherapy of cancer. However current approaches are often limited in their potential to induce an effective anti-tumor response. Dendritic cells (DC) are natural adjuvants for the induction of antigen specific T cell response. They have been successfully used in clinical pilot trials to induce tumor specific immunity as well as clinical response in selected patients. Current research focuses on optimization of DC source, choice of antigen, antigen loading, mode of injection, as well as immuno-monitoring. Finally, a variety of immune escape mechanisms are operative at the tumor site and have to be overcome for successful vaccination.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1038/sj.onc.1204095
- PMID 11426654
- Persistent URL
- https://sonar.ch/global/documents/280071
Statistics
Document views: 8
File downloads:
- fulltext.pdf: 0